J&J reports two-year psoriasis drug data for high-impact sites

Johnson & Johnson (J&J) has released two-year data from its Phase 3 ICONIC-TOTAL study on the effectiveness of its oral medication, ICOTYDE (icotrokinra), in treating plaque psoriasis in high-impact areas such as the scalp, genitals, hands, and feet. The study, presented at the European Academy of Dermatology and Venereology Congress 2026, showed that 60% of patients with scalp psoriasis achieved complete skin clearance after 112 weeks, while 89% of patients with genital psoriasis and 63% with hand and foot psoriasis reached complete clearance.

Overall skin clearance rates increased from 57% at Week 16 to 67% at Week 24 and 70% at Week 112. The company also noted improvements in nail psoriasis, with a mean percentage improvement in the modified Nail Psoriasis Severity Index rising from 33% at Week 16 to 62% at Week 52 and 71% at Week 112. The safety profile of ICOTYDE remained consistent, with no new safety signals identified.

ICOTYDE is approved for treating moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older weighing at least 40 kg in the U.S., Europe, Japan, and China.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.